Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 6Leukemia 5Neoplasms by Histologic Type 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Hematologic Diseases 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myeloid, Chronic-Phase 2Immunoproliferative Disorders 2Immune System Diseases 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Piebaldism 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Malignant Hepatobiliary Neoplasm 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Carcinoma, Squamous Cell 1Blast Crisis 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 27Cetuximab 17Radiotherapy 14Carboplatin 14pembrolizumab 11Paclitaxel 11Drug Therapy 8Radiotherapy, Intensity-Modulated 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7Radiation 6Docetaxel 5130-nm albumin-bound paclitaxel 5Panitumumab 4Chemoradiotherapy 3Capecitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Afatinib 3selinexor 2figitumumab 2Restraint, Physical 2Radiosurgery 2Methotrexate 2Lapatinib 2Everolimus 2Esophagectomy 2Cyclophosphamide 2zalutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Squamous Cell × ponatinib × Clear all
NCT01761747 2014-12-23

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Dana-Farber Cancer Institute

Phase 2/3 Terminated
3 enrolled 9 charts
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡